Answers are grounded in this paper and cite their sources.
Dual-function nanoemulsions block viral entry and improve oxygen delivery in severe COVID-19, suggesting a new therapeutic approach.
Severe COVID-19 is characterized by viral propagation and acute respiratory distress syndrome (ARDS), often necessitating mechanical ventilation with associated complications. We designed a dual-function nanoemulsion to combat both issues simultaneously. Perfluorooctyl bromide (PFOB) nanoemulsions, stabilized by DSPE-PEG 2000 -biotin, were functionalized with recombinant human ACE2-core streptavidin (rhACE2-coreSA) fusion proteins. These ACE2-tethered nanoparticles act as decoys, effectively binding and neutralizing SARS-CoV-2 spike protein pseudotyped lentivirus (D614G variant) in vitro, blocking infection of ACE2-expressing HEK293T cells by up to 99%. Concurrently, the high oxygen solubility of the PFOB core offers significant potential for oxygen delivery. This ACE2-anchored oxygen carrier nanoemulsion represents a promising therapeutic strategy against SARS-CoV-2 and its variants by inhibiting viral entry and mitigating hypoxia.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: